Could you provide a PowerPoint slide summarizing anti‑myelin‑associated glycoprotein (MAG) neuropathy, including its definition, pathophysiology, clinical presentation, diagnostic criteria, and treatment recommendations?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Anti-MAG Neuropathy: PowerPoint Summary

Definition

Anti-MAG neuropathy is a rare IgM-mediated autoimmune demyelinating peripheral neuropathy caused by antibodies against myelin-associated glycoprotein, typically associated with monoclonal gammopathy of undetermined significance (MGUS) or Waldenström's macroglobulinemia. 1


Pathophysiology

The disease is driven by IgM paraprotein antibodies that directly target MAG on peripheral nerve myelin, causing distal-predominant demyelination. 1

  • IgM antibodies bind to MAG on the outermost myelin lamellae
  • Results in characteristic "widely spaced myelin" on electron microscopy
  • Approximately 90% of cases harbor the MYD88L265P mutation 2
  • Sulfated glucuronyl paragloboside antibodies may also be detected 1
  • Disease progression is variable: some cases remain indolent for years/decades, others show acute accelerations 1

Clinical Presentation

The typical presentation is a predominantly sensory ataxic symmetric demyelinating distal neuropathy starting in the legs, with gait disturbance and tremor in the arms as the predominant disabling symptoms. 1

Key Clinical Features:

  • Sensory symptoms: Distal numbness, paresthesias, prominent deep sensory ataxia
  • Motor symptoms: Distal weakness (less prominent than sensory features)
  • Ataxia: Gait instability, upper limb tremor
  • Distribution: Symmetric, distal-to-proximal gradient
  • Progression: Slowly progressive over years
  • Male predominance
  • Estimated prevalence: 0.28 per 100,000 population in Japan 3

Diagnostic Criteria

Essential Diagnostic Elements:

1. Serological Testing:

  • Anti-MAG antibody titer ≥10,000 BTU (Bühlmann titration units) provides 100% specificity for typical anti-MAG neuropathy 4
  • Titer ≥1,500 BTU offers 96% specificity and reduces likelihood of immune-treatable CIDP 4
  • IgM monoclonal gammopathy on serum protein electrophoresis with immunofixation
  • Mass-Fix (mass spectrophotometry) superior to standard SPIEP for detecting IgM gammopathy 4

2. Electrodiagnostic Studies:

  • Prolonged distal latencies (hallmark finding)
  • Demyelinating pattern: may show demyelinating, axonal, or mixed patterns 1
  • Distal-predominant demyelination with secondary axonal loss
  • Caution: Nerves can become inexcitable in advanced disease, masking demyelinating abnormalities 5

3. Additional Testing:

  • Complete blood count, comprehensive metabolic panel
  • Cerebrospinal fluid analysis: typically elevated protein
  • Serum and urine protein electrophoresis with immunofixation
  • Nerve biopsy (if diagnosis uncertain): shows widely spaced myelin on electron microscopy 3
  • Bone marrow biopsy to exclude B-cell proliferative disorders 6

Treatment Recommendations

First-Line Treatment:

IVIG and rituximab are the most frequently used treatments, though evidence shows benefit in only approximately 50% of patients. 1

  • Rituximab: Most common first-line agent
    • Standard dosing or individualized low-dose regimens (100 mg Day 1,500 mg Day 2) for elderly/comorbid patients 6
    • Target: ≥50-60% reduction in serum IgM for clinical improvement 1, 4
    • Important: Two RCTs showed no convincing evidence of benefit 1

Emerging Therapies:

Bruton tyrosine kinase (BTK) inhibitors show promise, particularly in MYD88-mutant cases:

  • Tirabrutinib (second-generation BTK inhibitor): for rituximab-refractory cases 1
  • Ibrutinib/Zanubrutinib: Emerging options 4
  • Particularly effective in patients with MYD88L265P mutation 7, 3

Therapies with Limited/No Benefit:

Standard CIDP treatments are ineffective in anti-MAG neuropathy: 8

  • Corticosteroids: Generally ineffective 3
  • IVIG alone: Response rate only 49% 1
  • Plasma exchange (TPE): Category III indication (Grade 1C) - may produce only transient response 1
    • 40% had transient effect, most relapsed after stopping 1
    • More effective for IgG/IgA MGUS than IgM 1

Special Considerations:

For patients with immunologic manifestations (e.g., anti-MAG neuropathy) in Waldenström's macroglobulinemia, rituximab single-agent therapy should be considered, particularly in frail patients less likely to tolerate chemoimmunotherapy. 9


Treatment Algorithm

For progressive, functionally impairing disease:

  1. Confirm diagnosis: Anti-MAG titer ≥10,000 BTU + IgM gammopathy + typical clinical/electrodiagnostic features
  2. Test for MYD88L265P mutation (guides BTK inhibitor use)
  3. First-line: Rituximab (standard or low-dose individualized regimen)
  4. Monitor: Target ≥50-60% IgM reduction
  5. If rituximab-refractory: BTK inhibitors (tirabrutinib, ibrutinib, zanubrutinib) - especially if MYD88-mutant
  6. Avoid: Standard CIDP therapies (steroids, IVIG monotherapy, plasma exchange as primary treatment)

Key Pitfalls to Avoid

  • Do not treat as CIDP: Standard CIDP therapies are ineffective 8
  • Do not rely on intermediate anti-MAG titers (1:320-1:1000): Can occur in CIDP; use ≥1,500 BTU cutoff 4
  • Do not use plasma exchange as primary therapy: Only produces transient responses 1
  • Do not overlook IgM gammopathy: Use Mass-Fix for superior detection 4
  • Do not delay BTK inhibitor consideration: Particularly effective in MYD88-mutant, rituximab-refractory cases 1, 7
  • Do not treat asymptomatic or non-progressive disease: Reserve treatment for functionally impairing, progressive neuropathy 5

Prognosis & Monitoring

  • Disease can remain indolent for years then enter progressive phase 5
  • Treatment trials may require 2 years duration to demonstrate efficacy 5
  • Optimal outcome measures: Neuropathy Impairment Score of Lower Extremities (NIS-LL) + Lower Limb Function (LLF) score 5
  • Monitor INCAT disability scores and summated CMAP for treatment response 4
  • Presence of IgM gammopathy (even without high anti-MAG titers) correlates with worse treatment response 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.